These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 12584744)

  • 1. In vivo mapping of fractional plasma volume (fpv) and endothelial transfer coefficient (Kps) in solid tumors using a macromolecular contrast agent: correlation with histology and ultrastructure.
    Marzola P; Farace P; Calderan L; Crescimanno C; Lunati E; Nicolato E; Benati D; Degrassi A; Terron A; Klapwijk J; Pesenti E; Sbarbati A; Osculati F
    Int J Cancer; 2003 Apr; 104(4):462-8. PubMed ID: 12584744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gadopentetate dimeglumine versus ultrasmall superparamagnetic iron oxide for dynamic contrast-enhanced MR imaging of tumor angiogenesis in human colon carcinoma in mice.
    de Lussanet QG; Backes WH; Griffioen AW; van Engelshoven JM; Beets-Tan RG
    Radiology; 2003 Nov; 229(2):429-38. PubMed ID: 14595147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of dynamic contrast-enhanced magnetic resonance imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media.
    Daldrup H; Shames DM; Wendland M; Okuhata Y; Link TM; Rosenau W; Lu Y; Brasch RC
    Pediatr Radiol; 1998 Feb; 28(2):67-78. PubMed ID: 9472047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI.
    Li KL; Wilmes LJ; Henry RG; Pallavicini MG; Park JW; Hu-Lowe DD; McShane TM; Shalinsky DR; Fu YJ; Brasch RC; Hylton NM
    J Magn Reson Imaging; 2005 Oct; 22(4):511-9. PubMed ID: 16161072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
    Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
    Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media.
    Daldrup H; Shames DM; Wendland M; Okuhata Y; Link TM; Rosenau W; Lu Y; Brasch RC
    AJR Am J Roentgenol; 1998 Oct; 171(4):941-9. PubMed ID: 9762973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic resonance imaging assays for dimethyl sulfoxide effect on cancer vasculature.
    Cyran CC; Sennino B; Chaopathomkul B; Fu Y; Rogut V; Shames DM; Wendland MF; McDonald DM; Brasch RC
    Invest Radiol; 2008 May; 43(5):298-305. PubMed ID: 18424950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights.
    Turetschek K; Preda A; Novikov V; Brasch RC; Weinmann HJ; Wunderbaldinger P; Roberts TP
    J Magn Reson Imaging; 2004 Jul; 20(1):138-44. PubMed ID: 15221819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DCE-MRI using small-molecular and albumin-binding contrast agents in experimental carcinomas with different stromal content.
    Farace P; Merigo F; Fiorini S; Nicolato E; Tambalo S; Daducci A; Degrassi A; Sbarbati A; Rubello D; Marzola P
    Eur J Radiol; 2011 Apr; 78(1):52-9. PubMed ID: 19443159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic contrast-enhanced micro-computed tomography correlates with 3-dimensional fluorescence ultramicroscopy in antiangiogenic therapy of breast cancer xenografts.
    Pöschinger T; Renner A; Eisa F; Dobosz M; Strobel S; Weber TG; Brauweiler R; Kalender WA; Scheuer W
    Invest Radiol; 2014 Jul; 49(7):445-56. PubMed ID: 24598441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-modal magnetic resonance imaging and histology of vascular function in xenografts using macromolecular contrast agent hyperbranched polyglycerol (HPG-GdF).
    Baker JH; McPhee KC; Moosvi F; Saatchi K; Häfeli UO; Minchinton AI; Reinsberg SA
    Contrast Media Mol Imaging; 2016; 11(1):77-88. PubMed ID: 26268906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of tumor angiogenesis: dynamic contrast-enhanced MRI with paramagnetic nanoparticles compared with Gd-DTPA in a rabbit Vx-2 tumor model.
    Kassner A; Thornhill RE; Liu F; Winter PM; Caruthers SD; Wickline SA; Lanza GM
    Contrast Media Mol Imaging; 2010; 5(3):155-61. PubMed ID: 20586031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor microvasculature observed using different contrast agents: a comparison between Gd-DTPA-Albumin and B-22956/1 in an experimental model of mammary carcinoma.
    Boschi F; Marzola P; Sandri M; Nicolato E; Galiè M; Fiorini S; Merigo F; Lorusso V; Chaabane L; Sbarbati A
    MAGMA; 2008 May; 21(3):169-76. PubMed ID: 18317830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model.
    Marzola P; Degrassi A; Calderan L; Farace P; Crescimanno C; Nicolato E; Giusti A; Pesenti E; Terron A; Sbarbati A; Abrams T; Murray L; Osculati F
    Clin Cancer Res; 2004 Jan; 10(2):739-50. PubMed ID: 14760097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice.
    de Lussanet QG; Langereis S; Beets-Tan RG; van Genderen MH; Griffioen AW; van Engelshoven JM; Backes WH
    Radiology; 2005 Apr; 235(1):65-72. PubMed ID: 15731376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The temporal correlation of dynamic contrast-enhanced magnetic resonance imaging with tumor angiogenesis in a murine glioblastoma model.
    Veeravagu A; Hou LC; Hsu AR; Cai W; Greve JM; Chen X; Tse V
    Neurol Res; 2008 Nov; 30(9):952-9. PubMed ID: 18662497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlative dynamic contrast MRI and microscopic assessments of tumor vascularity in RIP-Tag2 transgenic mice.
    Sennino B; Raatschen HJ; Wendland MF; Fu Y; You WK; Shames DM; McDonald DM; Brasch RC
    Magn Reson Med; 2009 Sep; 62(3):616-25. PubMed ID: 19526501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decrease in tumor apparent permeability-surface area product to a MRI macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation.
    Daldrup-Link HE; Okuhata Y; Wolfe A; Srivastav S; Øie S; Ferrara N; Cohen RL; Shames DM; Brasch RC
    Microcirculation; 2004; 11(5):387-96. PubMed ID: 15280064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of tyrosine kinase receptors by SU6668 promotes abnormal stromal development at the periphery of carcinomas.
    Farace P; Galiè M; Merigo F; Daducci A; Calderan L; Nicolato E; Degrassi A; Pesenti E; Sbarbati A; Marzola P
    Br J Cancer; 2009 May; 100(10):1575-80. PubMed ID: 19384298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer.
    Preda A; Novikov V; Möglich M; Turetschek K; Shames DM; Brasch RC; Cavagna FM; Roberts TP
    J Magn Reson Imaging; 2004 Nov; 20(5):865-73. PubMed ID: 15503324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.